209 related articles for article (PubMed ID: 22842597)
1. Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.
Gerna G; Lilleri D; Furione M; Castiglioni B; Meloni F; Rampino T; Agozzino M; Arbustini E
New Microbiol; 2012 Jul; 35(3):279-87. PubMed ID: 22842597
[TBL] [Abstract][Full Text] [Related]
2. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection.
Gerna G; Lilleri D; Furione M; Baldanti F
New Microbiol; 2011 Jul; 34(3):229-54. PubMed ID: 21811744
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
4. Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients.
Lilleri D; Gerna G; Bruno F; Draghi P; Gabanti E; Fornara C; Meloni F
New Microbiol; 2013 Jul; 36(3):267-77. PubMed ID: 23912868
[TBL] [Abstract][Full Text] [Related]
5. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
6. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
Lilleri D; Zelini P; Fornara C; Comolli G; Revello MG; Gerna G
Clin Immunol; 2009 Jun; 131(3):395-403. PubMed ID: 19268633
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
8. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.
Gabanti E; Bruno F; Lilleri D; Fornara C; Zelini P; Cane I; Migotto C; Sarchi E; Furione M; Gerna G
PLoS One; 2014; 9(8):e106044. PubMed ID: 25166270
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
[TBL] [Abstract][Full Text] [Related]
10. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.
Brestrich G; Zwinger S; Roemhild A; Noutsias M; Rohde M; Keeren K; Sawitzki B; Volk HD; Reinke P; Hammer MH
J Immunother; 2009; 32(9):932-40. PubMed ID: 19816188
[TBL] [Abstract][Full Text] [Related]
11. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
Gerna G; Lilleri D
Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
Kamar N; Mengelle C; Yahyaoui S; Sandres-Sauné K; Durand D; Izopet J; Rostaing L
J Clin Virol; 2005 May; 33(1):35-42. PubMed ID: 15797363
[TBL] [Abstract][Full Text] [Related]
13. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
[TBL] [Abstract][Full Text] [Related]
14. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Baldanti F; Lilleri D; Campanini G; Comolli G; Ridolfo AL; Rusconi S; Gerna G
J Antimicrob Chemother; 2004 Mar; 53(3):536-9. PubMed ID: 14739146
[TBL] [Abstract][Full Text] [Related]
15. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
[TBL] [Abstract][Full Text] [Related]
16. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
17. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
20. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
